CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
liraglutide +2 moredrug
Likely dose
liraglutide 1.8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01232946
NCT01232946N/ACompleted
CompareCT.gov

Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake

Indiana University·interventional·Posted Nov 2, 2010·Updated Aug 7, 2019

In Brief

A clinical study evaluating liraglutide, insulin detemir, and 1 other intervention for Type 2 Diabetes. Completed, enrolled 30 participants across 1 site.

Detailed Summary

27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or liraglutide plus detemir (9 subjects per group), on a background of metformin 2000 mg per day. After 3 months' treatment, PET measurements of myocardial fuel selection will take place, under fasting conditions in the morning following that day's treatment injection(s).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsNovo Nordisk A/S

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2, 2010
Enrollment StartJan 1, 2012
Primary CompletionSep 8, 2017
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 15.7 years ago

Interventions

liraglutidedrug

1.8mg subcutaneous qd for 3 months

insulin detemirdrug

5units subcutaneous bid titrated to fasting glucose of \<130mg/dL for 3 months

liraglutide plus insulin detemirdrug

liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose \<130mg/dL for 3 months.